Is Recursion Pharmaceuticals profitable in 2026?

No. Recursion posted a FY2025 net loss of $644.8M against total revenue of just $74.7M (as of the 2026-02-25 10-K), with R&D spend of $475.3M. The company has never had a drug reach market since founding in 2013.

Did Recursion Pharmaceuticals have layoffs?

Yes. In June 2025 Recursion cut about 20% of its roughly 800-person workforce (~160 employees) to streamline its pipeline, incurring about $11M in severance costs. Headcount fell from 1,237 in 2023 to 751 by end of 2025.

Who owns Recursion Pharmaceuticals?

Recursion is publicly traded on Nasdaq under RXRX with no parent company. It absorbed Exscientia plc via an all-stock merger completed November 20, 2024, with legacy Recursion shareholders holding about 74% of the combined company.

Is Isomorphic Labs a bigger threat than Recursion's other rivals?

Yes, as of mid 2026. Alphabet-backed Isomorphic Labs has raised about $2.7B, co-authored AlphaFold 3, released its IsoDDE engine in February 2026, and signed Lilly and Novartis deals worth up to $2.9B, with dosing of its first AI-designed compound expected by end of 2026.

How much cash runway does Recursion Pharmaceuticals have?

Recursion reported a $754M cash balance at Q4 2025 with guided runway into early 2028, against roughly $399.2M in FY2025 cash operating expense. That gives roughly 1.5 to 2 years of runway before the company needs new capital or partner cash.

Has Recursion Pharmaceuticals ever brought a drug to market?

No. Founded in November 2013 in Salt Lake City, Recursion has not gained FDA approval for any drug in over 12 years. Its furthest clinical result is REC-4881 showing a 43% median polyp reduction at 12 weeks in FAP, reported 2026-02-26, with FDA registrational-pathway talks underway in H1 2026.

AI companies and labs · United States

Recursion Pharmaceuticals

recursion.com ↗

AI-driven drug discovery company using proprietary lab imaging data to find new medicines.

Losing its protection

Assessed 20 July 2026 · Evidence as of 20 July 2026

The structural protection is eroding.

On the recordSince 20 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: FDA decision on REC-4881/FAP registrational pathway

The call

Recursion has real data and one clinical win, but a short cash runway and a faster-moving Isomorphic Labs make the next 18 months decisive.

Recursion uses artificial intelligence and special lab images of human cells to design new medicines faster than traditional methods. The company has built something hard to copy: 65 petabytes of cell images and a billion human neurons in a dish that no other company owns, and it showed early success with a colon polyp drug in human tests. However, Recursion is spending $400 million per year while making only $75 million, which means it will run out of money by early 2028 unless something changes. Isomorphic Labs, backed by Google and DeepMind with $2.7 billion in funding, is moving faster on similar AI drug design and already has deal commitments from Eli Lilly, Novartis, and Johnson & Johnson, plus plans to have its first AI-designed drug ready for human dosing by the end of 2026. The one thing that could save Recursion is either a major pharmaceutical partner giving it enough cash upfront or FDA approval of its colon polyp drug, which would both extend the runway and prove the approach works.

Why

AI pressure: Isomorphic Labs. Isomorphic's AlphaFold-based engine is landing bigger pharma deals and aims to dose its first AI-designed drug by end of 2026, ahead of Recursion. Could AI do the core job? Only partly.

Bigger players: Roche/Genentech, Sanofi, Bayer, Merck KGaA. These partners fund Recursion today but face no real barrier to building similar AI discovery capability in-house. Could a giant copy it? Probably.

What protects it. A 65 petabyte proprietary imaging dataset and over 1 trillion iPSC neuron images that partners cannot easily replicate or buy elsewhere.

What would change this call

Isomorphic Labs doses its first AI-designed compound by end of 2026. Would show a rival converting AI drug design to clinic faster than Recursion.
FDA registrational pathway decision on REC-4881/FAP in H2 2026. Would show whether Recursion's data moat can actually reach an approval endpoint.
Terms of Recursion's next capital raise before 2028 runway end. A dilutive down-round would signal financial deterioration versus a non-dilutive partner deal.

Key numbers

$754M cash, runway into early 2028 (Q4 2025)
$644.8M net loss in FY2025 (2026-02-25)
Stock near 52-week low, ~$2.90/share (2026-07-20)

Named risks

Cash runway extends only into early 2028 against $400M-plus annual burn rate. Severity: high
No FDA-approved drug in over 12 years since 2013 founding despite platform claims. Severity: high
Heavily shorted stock trading near multi-year lows signals persistent investor skepticism. Severity: medium
Isomorphic Labs and Insilico Medicine advancing faster toward clinical/regulatory milestones. Severity: medium
Revenue concentration in a handful of pharma partner milestone payments. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Isomorphic Labs	gaining on	Lilly/Novartis deals up to $2.9B, IsoDDE engine Feb 2026, dosing first AI drug by end 2026
Insilico Medicine	gaining on	ISM001-055 posted positive Phase 2a efficacy data, first AI-designed drug clinical win, Nov 2025
Schrodinger	contesting	Competing SaaS plus proprietary pipeline model with partners including BMS and Novartis, 2026
Roche/Genentech, Sanofi, Bayer, Merck KGaA	contesting	Remain paying partners with milestone deals but building in-house AI discovery capability, 2026

Questions people ask

Is Recursion Pharmaceuticals profitable in 2026?: No. Recursion posted a FY2025 net loss of $644.8M against total revenue of just $74.7M (as of the 2026-02-25 10-K), with R&D spend of $475.3M. The company has never had a drug reach market since founding in 2013.
Did Recursion Pharmaceuticals have layoffs?: Yes. In June 2025 Recursion cut about 20% of its roughly 800-person workforce (~160 employees) to streamline its pipeline, incurring about $11M in severance costs. Headcount fell from 1,237 in 2023 to 751 by end of 2025.
Who owns Recursion Pharmaceuticals?: Recursion is publicly traded on Nasdaq under RXRX with no parent company. It absorbed Exscientia plc via an all-stock merger completed November 20, 2024, with legacy Recursion shareholders holding about 74% of the combined company.
Is Isomorphic Labs a bigger threat than Recursion's other rivals?: Yes, as of mid 2026. Alphabet-backed Isomorphic Labs has raised about $2.7B, co-authored AlphaFold 3, released its IsoDDE engine in February 2026, and signed Lilly and Novartis deals worth up to $2.9B, with dosing of its first AI-designed compound expected by end of 2026.
How much cash runway does Recursion Pharmaceuticals have?: Recursion reported a $754M cash balance at Q4 2025 with guided runway into early 2028, against roughly $399.2M in FY2025 cash operating expense. That gives roughly 1.5 to 2 years of runway before the company needs new capital or partner cash.
Has Recursion Pharmaceuticals ever brought a drug to market?: No. Founded in November 2013 in Salt Lake City, Recursion has not gained FDA approval for any drug in over 12 years. Its furthest clinical result is REC-4881 showing a 43% median polyp reduction at 12 weeks in FAP, reported 2026-02-26, with FDA registrational-pathway talks underway in H1 2026.

Timeline

2026-07-20RXRX trades near $2.90-2.93, market cap ~$1.56-1.77B, far below $42.81 all-time high
2026-05-06FDA engagement on REC-4881/FAP registrational pathway; TUPELO trial expanded to 18+ patients
2026-02-25FY2025 results: $74.7M revenue (+27% YoY), $644.8M net loss, $475.3M R&D spend
2026-01-01Najat Khan becomes CEO/President; co-founder Chris Gibson moves to Chairman
2025-11-05Leadership transition announced naming Najat Khan incoming CEO
2025-06-10Recursion lays off ~20% of workforce (~160 employees), ~$11M severance cost
2024-11-20Recursion completes ~$688M all-stock merger with Exscientia plc
2021-04-16Recursion IPOs on Nasdaq at $18/share, raising ~$502M gross
2013-11-04Recursion Pharmaceuticals founded in Salt Lake City by Gibson, Li, and Borgeson

Revision history

20 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Safe Superintelligence Inc.Mistral AI Cohere